Page last updated: 2024-11-02

pirenzepine and Hypertriglyceridemia

pirenzepine has been researched along with Hypertriglyceridemia in 7 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.

Research Excerpts

ExcerptRelevanceReference
"Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents."5.31Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001)
" A small number of reports documenting modest hypertriglyceridemia related to newer antipsychotics have implicated fluperlapine, clozapine, and, most recently, olanzapine."3.71Novel antipsychotics and severe hyperlipidemia. ( Meyer, JM, 2001)
"Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents."1.31Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's5 (71.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stoner, SC1
Dubisar, BM1
Khan, R1
Farrar, CD1
Wetterling, T1
Sheitman, BB1
Bird, PM1
Binz, W1
Akinli, L1
Sanchez, C1
Osser, DN1
Najarian, DM1
Dufresne, RL1
Nguyen, M1
Murphy, T1
Meyer, JM1
Domon, SE1
Webber, JC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]Phase 416 participants (Actual)Interventional2005-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Body Mass Index (BMI)

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionkg/m^2 (Mean)
Aripiprazole-0.4
Placebo0.3

Change From Baseline in Fasting Total Cholesterol

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-3
Placebo9

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole0.4
Placebo0.6

Change From Baseline in Low-density Lipoprotein (LDL)

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-0.2
Placebo3.1

Change From Baseline in Triglycerides

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionmg/dL (Mean)
Aripiprazole-51.7
Placebo47.6

Change From Baseline in Waist-hip Ratio (WHR)

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventioncm (Mean)
Aripiprazole0.0
Placebo0.0

Change From Baseline in Weight (Lbs)

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Interventionlbs (Mean)
Aripiprazole-2.9
Placebo2.1

Reviews

1 review available for pirenzepine and Hypertriglyceridemia

ArticleYear
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
    Medizinische Klinik (Munich, Germany : 1983), 2003, Jul-15, Volume: 98, Issue:7

    Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Humans; Hy

2003

Trials

1 trial available for pirenzepine and Hypertriglyceridemia

ArticleYear
Olanzapine increases weight and serum triglyceride levels.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:11

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat

1999

Other Studies

5 other studies available for pirenzepine and Hypertriglyceridemia

ArticleYear
Severe hypertriglyceridemia associated with olanzapine.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:10

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Hospitalization; Humans; Hypertriglyceridemia; Male; O

2002
Olanzapine-induced elevation of plasma triglyceride levels.
    The American journal of psychiatry, 1999, Volume: 156, Issue:9

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administr

1999
Olanzapine and hypertriglyceridemia.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2001, Volume: 40, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Humans; Hypertriglyceridemia; Male;

2001
Novel antipsychotics and severe hyperlipidemia.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Hyperl

2001
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.
    Journal of child and adolescent psychopharmacology, 2001,Fall, Volume: 11, Issue:3

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Humans; Hyperglycemia; Hypertriglyceridemia; Male

2001